Francisco Espejo-Porras
Overview
Explore the profile of Francisco Espejo-Porras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mowry F, Espejo-Porras F, Jin S, Quadri Z, Wu L, Bertolio M, et al.
Neurobiol Dis
. 2023 Jun;
184:106213.
PMID: 37364689
Female biased pathology and cognitive decline in Alzheimer's disease (AD) have been consistently observed with unclear underlying mechanisms. Although brain sphingolipid ceramide is elevated in AD patients, whether and how...
2.
Rodriguez-Cueto C, Garcia-Toscano L, Santos-Garcia I, Gomez-Almeria M, Gonzalo-Consuegra C, Espejo-Porras F, et al.
Br J Pharmacol
. 2021 Jan;
178(6):1373-1387.
PMID: 33486755
Cannabinoids form a singular group of plant-derived compounds, endogenous lipids and synthetic derivatives with multiple therapeutic effects exerted by targeting different elements of the endocannabinoid system. One of their therapeutic...
3.
Yelick J, Men Y, Jin S, Seo S, Espejo-Porras F, Yang Y
Exp Neurol
. 2020 Jul;
333:113414.
PMID: 32712030
MicroRNAs (miRs) are powerful regulators of CNS development and diseases. Plasma and cerebrospinal fluid (CSF) miRs have recently been implicated as potential new sources for biomarker development. Previously we showed...
4.
Fernandez-Trapero M, Perez-Diaz C, Espejo-Porras F, de Lago E, Fernandez-Ruiz J
Biomolecules
. 2020 Feb;
10(2).
PMID: 32054131
The phytocannabinoid-based medicine Sativex is currently marketed for the treatment of spasticity and pain in multiple sclerosis patients and is being investigated for other central and peripheral pathological conditions. It...
5.
Rodriguez-Cueto C, Santos-Garcia I, Garcia-Toscano L, Espejo-Porras F, Bellido M, Fernandez-Ruiz J, et al.
Biochem Pharmacol
. 2018 Aug;
157:217-226.
PMID: 30076846
Antioxidant phytocannabinoids, synthetic compounds targeting the CB receptor, and inhibitors of the endocannabinoid inactivation afforded neuroprotection in SOD1 mutant mice, a model of ALS. These effects may involve the activation...
6.
Espejo-Porras F, Garcia-Toscano L, Rodriguez-Cueto C, Santos-Garcia I, de Lago E, Fernandez-Ruiz J
Br J Pharmacol
. 2018 Mar;
176(10):1585-1600.
PMID: 29574689
Background And Purpose: Cannabinoid CB receptors are up-regulated in reactive microglia in the spinal cord of TDP-43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether...
7.
Espejo-Porras F, Fernandez-Ruiz J, de Lago E
Amyotroph Lateral Scler Frontotemporal Degener
. 2018 Jan;
19(5-6):377-386.
PMID: 29334787
Objective: We have investigated the endocannabinoid system in the motor cortex of motor neuron disease (MND) patients. Methods: Post-mortem samples from MND patients and controls were used for immunostaining and/or...
8.
Fernandez-Trapero M, Espejo-Porras F, Rodriguez-Cueto C, Coates J, Perez-Diaz C, de Lago E, et al.
Dis Model Mech
. 2017 Jan;
10(5):551-558.
PMID: 28069688
Targeting of the CB receptor results in neuroprotection in the SOD1 mutant mouse model of amyotrophic lateral sclerosis (ALS). The neuroprotective effects of CB receptors are facilitated by their upregulation...
9.
Moreno-Martet M, Feliu A, Espejo-Porras F, Mecha M, Carrillo-Salinas F, Fernandez-Ruiz J, et al.
Mult Scler Relat Disord
. 2015 Nov;
4(6):505-11.
PMID: 26590655
Sativex(®), an equimolecular combination of Δ(9)-tetrahydrocannabinol-botanical drug substance (Δ(9)-THC-BDS) and cannabidiol-botanical drug substance (CBD-BDS), is a licensed medicine that may be prescribed for alleviating specific symptoms of multiple sclerosis (MS)...
10.
Espejo-Porras F, Piscitelli F, Verde R, Ramos J, Di Marzo V, de Lago E, et al.
J Neuroimmune Pharmacol
. 2015 Mar;
10(2):233-44.
PMID: 25819934
Because of their neuroprotective properties, cannabinoids are being investigated in neurodegenerative disorders, mainly in preclinical studies. These disorders also include amyotrophic lateral sclerosis (ALS), a degenerative disease produced by the...